Market Capitalization (Millions $) |
26 |
Shares
Outstanding (Millions) |
7 |
Employees |
- |
Revenues (TTM) (Millions $) |
105 |
Net Income (TTM) (Millions $) |
41 |
Cash Flow (TTM) (Millions $) |
-11 |
Capital Exp. (TTM) (Millions $) |
0 |
Mei Pharma Inc
Mei Pharma Inc is a pharmaceutical company headquartered in San Diego, California. The company focuses on the development and commercialization of innovative cancer therapies, with a specific emphasis on acute myeloid leukemia (AML) and other hematologic malignancies. Mei Pharma's mission is to deliver novel drugs that can significantly improve the lives of patients suffering from these diseases.
The company's pipeline consists of both clinical and preclinical stage drug candidates. Their lead product candidate, ME-401, is an oral selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor being developed for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). ME-401 has shown promising results in early-stage clinical trials.
In addition to ME-401, Mei Pharma also has other drug candidates in development, including ME-344, a mitochondrial inhibitor for the treatment of HER2-negative breast cancer, and ME-402, a clinical stage selective PI3K delta inhibitor for the treatment of CLL and FL.
Mei Pharma is committed to advancing its drug candidates through rigorous clinical trials and regulatory processes to bring effective treatments to patients in need. The company collaborates with academic institutions, research organizations, and other pharmaceutical companies to accelerate the development of innovative cancer drugs.
Company Address: 11455 El Camino Real San Diego 92130 CA
Company Phone Number: 369-7100 Stock Exchange / Ticker: NASDAQ MEIP
|